Document is current
Any future updates will be listed below
-
Authors
Brandão, Luiz Eduardo Mateus
Zhang, Lei
Grip, Anastasia
Hong, Mun-Gwan
Kåks, Emil
Benfeitas, Rui
Sigurdardottir, Fjola
Blennow, Kaj
Zetterberg, Henrik
Espes, Daniel
Omland, Torbjørn
Khoonsari, Payam Emami
Benedict, Christian
Cedernaes, Jonathan
-
Funding
Funding for this research was provided by:
Horizon 2020 (965422, 965422, 965422)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2021-00057)
Stiftelsen Lars Hiertas Minne (FO2024-0746)
Fredrik och Ingrid Thurings Stiftelse (2023-067)
European Union’s Horizon Europe research and innovation program under the Marie Skłodowska-Curie grant agreement (101152757)
Uppsala Diabetes Center
Vetenskapsrådet (2022-00732, 2023-00356, 2022-02708)
Novo Nordisk Fonden (NNF23OC0081873)
Svenska Sällskapet för Medicinsk Forskning
Hjärnfonden (FO2023-0420)
Cancerfonden (22 2476 Pj)
Diabetesfonden (DIA2023-820)
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 8 April 2025
First Online: 29 April 2025
Declarations
:
: The study was approved by the regional Ethics Committee in Uppsala (Dnr 2014/242/1, Sweden) and was conducted following written and orally informed participant consent.
: Not applicable.
: KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
